Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination

NCT02149706 is registered in ClinicalTrials.gov with Immune Response BioPharma, Inc. as lead sponsor.

NCT NCT02149706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02149706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination
Lead sponsor
Immune Response BioPharma, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
March 9, 2020
Completion date
March 9, 2022
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis